Toggle navigation
About
Abstract
Editorial Board
Publication Schedule
Subscription & Newsletter
Contact
Issues
This issue
24-1/2
All issues
Download PDF
Download EPUB
Editor's Selection
This issue
24-1/2
Browse by topic
Browse by contributor
Dialogue & Opinion
Abstracts
Abstracts
Search
Classification List
Abstracted Journals
Index of Authors
News & Reports
Home
Abstracts
Journals
Journal #577
advertisement
Journal of Ocular Pharmacology and Therapeutics
28
Showing records 1 to 25 |
Display all abstracts in
Journal of Ocular Pharmacology and Therapeutics
109316
Preclinical Pharmacokinetic Profile of Topical Ophthalmic and Intravenous Delivery of QLS-101, a Novel ATP-Sensitive Potassium Channel Opening Ocular Hypotensive Agent
Roy Chowdhury U
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 332-346
109539
Activation of Sonic Hedgehog Signaling Pathway Regulates Human Trabecular Meshwork Cell Function
Wang X
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 430-438
109725
Intraocular Pressure and Eyedrop Usage Reduction with Intracameral Bimatoprost Implant
Xu W
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 398-403
109470
Efficacy of Topical 0.05% Cyclosporine A for Ocular Surface Disease Related to Topical Anti-Glaucoma Medications
Kim JG
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 389-397
109881
The Development of a SIBS Shunt to Treat Glaucoma
Pinchuk L
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 530-540
109471
Ocular Treatments Targeting Separate Prostaglandin Receptors in Mice Exhibit Alterations in Intraocular Pressure and Optic Nerve Lipidome
Arcuri J; Elbaz A
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 541-550
109539
Activation of Sonic Hedgehog Signaling Pathway Regulates Human Trabecular Meshwork Cell Function
Tan S
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 430-438
109470
Efficacy of Topical 0.05% Cyclosporine A for Ocular Surface Disease Related to Topical Anti-Glaucoma Medications
An JH
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 389-397
109316
Preclinical Pharmacokinetic Profile of Topical Ophthalmic and Intravenous Delivery of QLS-101, a Novel ATP-Sensitive Potassium Channel Opening Ocular Hypotensive Agent
Pervan-Steel CL
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 332-346
109725
Intraocular Pressure and Eyedrop Usage Reduction with Intracameral Bimatoprost Implant
Zhou P
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 398-403
109470
Efficacy of Topical 0.05% Cyclosporine A for Ocular Surface Disease Related to Topical Anti-Glaucoma Medications
Cho SY
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 389-397
109725
Intraocular Pressure and Eyedrop Usage Reduction with Intracameral Bimatoprost Implant
Kansara ND
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 398-403
109316
Preclinical Pharmacokinetic Profile of Topical Ophthalmic and Intravenous Delivery of QLS-101, a Novel ATP-Sensitive Potassium Channel Opening Ocular Hypotensive Agent
Sheeler R
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 332-346
109471
Ocular Treatments Targeting Separate Prostaglandin Receptors in Mice Exhibit Alterations in Intraocular Pressure and Optic Nerve Lipidome
Sharif NA
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 541-550
109539
Activation of Sonic Hedgehog Signaling Pathway Regulates Human Trabecular Meshwork Cell Function
Yang S
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 430-438
109471
Ocular Treatments Targeting Separate Prostaglandin Receptors in Mice Exhibit Alterations in Intraocular Pressure and Optic Nerve Lipidome
Bhattacharya SK
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 541-550
109316
Preclinical Pharmacokinetic Profile of Topical Ophthalmic and Intravenous Delivery of QLS-101, a Novel ATP-Sensitive Potassium Channel Opening Ocular Hypotensive Agent
Sookdeo HK
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 332-346
109539
Activation of Sonic Hedgehog Signaling Pathway Regulates Human Trabecular Meshwork Cell Function
Liu X
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 430-438
109725
Intraocular Pressure and Eyedrop Usage Reduction with Intracameral Bimatoprost Implant
Frankfort BJ
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 398-403
109470
Efficacy of Topical 0.05% Cyclosporine A for Ocular Surface Disease Related to Topical Anti-Glaucoma Medications
Lee CE
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 389-397
109539
Activation of Sonic Hedgehog Signaling Pathway Regulates Human Trabecular Meshwork Cell Function
Lei J
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 430-438
109316
Preclinical Pharmacokinetic Profile of Topical Ophthalmic and Intravenous Delivery of QLS-101, a Novel ATP-Sensitive Potassium Channel Opening Ocular Hypotensive Agent
Rogers B
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 332-346
109725
Intraocular Pressure and Eyedrop Usage Reduction with Intracameral Bimatoprost Implant
Blieden LS
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 398-403
109470
Efficacy of Topical 0.05% Cyclosporine A for Ocular Surface Disease Related to Topical Anti-Glaucoma Medications
Shim KY
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 389-397
109539
Activation of Sonic Hedgehog Signaling Pathway Regulates Human Trabecular Meshwork Cell Function
Li H
Journal of Ocular Pharmacology and Therapeutics
2023; 39: 430-438
«
1
2
»
Issue
24-1/2
Table of Contents
Editor's Selection
PDF
EPUB
Change Issue
26-1
25-4
25-3
25-2
25-1
24-4
24-3
24-1/2
23-4
23-3
23-2
23-1
22-4
22-3
22-2
22-1
21-4
21-3
21-2
21-1
20-4
20-3
20-2
20-1
19-4
19-3
19-2
19-1
18-4
18-3
18-2
18-1
17-4
17-3
17-2
17-1
16-4
16-3
16-2
16-1
15-4
15-3
15-2
15-1
14-4
14-3
14-2
14-1
13-4
13-3
13-2
13-1
12-4
12-3
12-2
12-1
11-4
11-3
11-2
11-1
10-4
10-3
10-2
10-1
9-4
9-3
9-2
9-1
8-4
8-3
8-2
8-1
7-3
7-2
7-1
6-3
6-2
6-1
5-3
5-2
5-1
4-3
4-2
4-1
3-3
3-2
3-1
2-3
2-2
2-1
1-3
1-2
1-1
advertisement
We would like to use Google Analytics to see which parts of the review are read. It is only used to count visits, never for advertising.
Privacy statement
Decline
Accept